AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Pinnacle Financial Partners Inc

Pinnacle Financial Partners Inc raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 32.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,908 shares of the company’s stock after buying an additional 953 shares during the period. Pinnacle Financial Partners Inc’s holdings in AstraZeneca were worth $304,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of AZN. McClarren Financial Advisors Inc. increased its stake in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new stake in shares of AstraZeneca during the second quarter worth $26,000. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the third quarter valued at $28,000. Pathway Financial Advisers LLC purchased a new position in AstraZeneca in the first quarter valued at $29,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN opened at $65.04 on Friday. The company has a market capitalization of $201.66 billion, a price-to-earnings ratio of 31.12, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average price of $75.79 and a 200 day moving average price of $78.38.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the business posted $0.87 EPS. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. Research analysts predict that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.